ABO 202

Drug Profile

ABO 202

Alternative Names: AAV-CLN1 - Abeona Therapeutics; ABO-202

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Abeona Therapeutics; University of North Carolina at Chapel Hill
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neuronal ceroid lipofuscinosis

Most Recent Events

  • 30 Mar 2017 Abeona Therapeutics has patents pending for AAV vector technology in USA
  • 21 Sep 2016 Preclinical trials in Neuronal ceroid lipofuscinosis in USA (Parenteral)
  • 21 Sep 2016 Abeona Therapeutics enters into licensing agreement with the University of North Carolina at Chapel Hill for AIM™ vector system
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top